

DAFTAR PUSTAKA

- Adrieanta, A., Windiastuti, E., & Handryastuti, S. 2016. Etiologi demam neutropenia pada anak dengan keganasan dan penggunaan skor klasifikasi Rondinelli. *Sari Pediatri*, 16(4), 229–235. <https://doi.org/10.14238/sp16.4.2014.229-35>
- Ahmed, N. M., & Flynn, P. M. 2024. *Fever in children with chemotherapy-induced neutropenia*. UpToDate. <https://www.uptodate.com/contents/fever-in-children-with-chemotherapy-induced-neutropenia>
- Alzu'bi, D. dkk., 2024. The microbial spectrum and antimicrobial resistance pattern in pediatric cancer patients with febrile neutropenia at King Abdullah University Hospital, Jordan. *Egyptian Pediatric Association Gazette*, 72(1). <https://doi.org/10.1186/s43054-024-00249-3>
- Angelino, G., et al. 2014. Etiology, clinical outcome, and laboratory features in children with neutropenia: Analysis of 104 cases. *Pediatr. Allergy Immunol.* 2014, 25, 283–289.
- Anoop, P., & Patil, C. N. 2020. Management of febrile neutropenia in children: Current approach and challenges. *Pediatric Infectious Disease*, 2(4), 135–139. <https://doi.org/10.5005/jp-journals-10081-1257>
- Astria, Y., Satari, H. I., Gunardi, H., & Sjakti, H. A. (2021). Microbiological profiles and prognostic factors of infection mortality in febrile neutropenic children with malignancy. *Paediatrica Indonesiana*, 61(5), 283–290. <https://doi.org/10.14238/pi61.5.2021.283-90>
- Bachlitzanaki, M., et al., 2023. Evaluation of febrile neutropenia in hospitalized patients with Neoplasia undergoing chemotherapy. *Microorganisms*, 11(10), 2547. <https://doi.org/10.3390/microorganisms11102547>
- Blijlevens, N. M., Logan, R. M., & Netea, M. G. 2009. Mucositis: From febrile neutropenia to febrile mucositis. *Journal of Antimicrobial Chemotherapy*, 63(Supplement 1), i36–i40. <https://doi.org/10.1093/jac/dkp081>
- Boeriu, E., et al., 2022. Diagnosis and management of febrile neutropenia in pediatric oncology patients—A systematic review. *Diagnostics*, 12(8), 1800. <https://doi.org/10.3390/diagnostics12081800>
- Budiana, I. N. G., & Febiani, M. 2017. Febrile neutropenia pada pasien paskakemoterapi. *Indonesian Journal of Cancer*, 11(2), 77–82. <https://doi.org/10.33371/ijoc.v11i2.505>
- Bush, K., & Bradford, P. A. 2016. B-lactams and β -lactamase inhibitors: An overview. *Cold Spring Harbor Perspectives in Medicine*, 6(8). <https://doi.org/10.1101/cshperspect.a025247>
- B.A. Hansen, et al., 2020. Febrile neutropenia in acute leukemia; epidemiology, etiology, pathophysiology and treatment. *Mediterr J Hematol Infect Diseases*, 12(1): e2020009, DOI: <http://dx.doi.org/10.4084/MJHID.2020.009>
- Campos, L. M., et al., 2023. Consensus document on the management of febrile neutropenia in paediatric haematology and oncology patients of the Spanish Society of Pediatric Infectious Diseases (SEIP) and the Spanish Society of Pediatric Hematology and Oncology (SEHOP). *Anales de Pediatría (English Edition)*, 98(6), 446–457. <https://doi.org/10.1016/j.anpede.2023.03.010>

- Cennamo, F. *et al.*, 2021. Update on febrile neutropenia in pediatric oncological patients undergoing chemotherapy. *Children*, 8(12), 1086. <https://doi.org/10.3390/children8121086>
- Chaudhuri, J. *et al.*, 2016. Evaluation of malnutrition as a predictor of adverse outcomes in febrile neutropenia associated with paediatric haematological malignancies. *Journal of Paediatrics and Child Health*, 52(7), 704–709. <https://doi.org/10.1111/jpc.13233>
- Contejean, A. *et al.*, 2023. Correction to: Advances in antibacterial treatment of adults with high-risk febrile neutropenia. *Journal of Antimicrobial Chemotherapy*, 78(11), 2784–2784. <https://doi.org/10.1093/jac/dkad304>
- Court, J. R. *et al.*, 2022. Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy: An 11-year multi-centre retrospective study. *Annals of Clinical Microbiology and Antimicrobials*, 21(1), 54. <https://doi.org/10.1186/s12941-022-00544-0>
- Crawford, J., Herndon, D., Gmitter, K., & Weiss, J. 2024. The impact of myelosuppression on quality of life of patients treated with chemotherapy. *Future Oncology*, 20(21), 1515–1530. <https://doi.org/10.2217/fon-2023-0513>
- Dabas, A. *et al.*, 2023. Factors associated with adverse outcome in pediatric oncology patients with FEBRILE NEUTROPENIA: A prospective cohort study from India. *JCO Global Oncology*, 9(Supplement_1), 117–117. https://doi.org/10.1200/go.2023.9.supplement_1.117
- Davis, K., & Wilson, S. 2019. Febrile neutropenia in paediatric oncology. *Paediatrics and Child Health*, 30(3), 93–97. <https://doi.org/10.1016/j.paed.2019.12.002>
- Deck, D. H., & Winston, L. G. 2012. Sulfonamides, Trimethoprim, & Quinolones. *Basic & Clinical Pharmacology*. (12th ed.) McGraw Hill.
- de Jonge, N. A. *et al.*, (2024). Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: Risk factors and the impact of mucositis severity. *Supportive Care in Cancer*, 32(9). <https://doi.org/10.1007/s00520-024-08776-w>
- de la Court, J. R. *et al.*, 2022. The Dutch working party on antibiotic policy (swab) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. *Infectious Diseases and Therapy*, 11(6), 2063–2098. <https://doi.org/10.1007/s40121-022-00700-1>
- Duzenli Kar, Y., Ozdemir, Z. C., & Bor, O. 2018. Evaluation of febrile neutropenic attacks of Pediatric Hematology-Oncology Patients. *Türk Pediatri Arşivi*, 52(4), 213–220. <https://doi.org/10.5152/turkpediatriars.2017.5312>
- Eshenshade, A. J. *et al.*, 2020. Prospective implementation of a risk prediction model for bloodstream infection safely reduces antibiotic usage in febrile pediatric cancer patients without severe neutropenia. *Journal of Clinical Oncology*, 38(27), 3150–3159. <https://doi.org/10.1200/jco.20.00591>
- Eyler, R. F., & Shvets, K. 2019. Clinical pharmacology of antibiotics. *Clinical Journal of the American Society of Nephrology*, 14(7), 1080–1090. <https://doi.org/10.2215/cjn.08140718>

- Gudiol, C. *et al.*, 2012. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. *Clinical Microbiology and Infection*, 19(5), 474–481. <https://doi.org/10.1111/j.1469-0691.2012.03879.x>
- Hajji M. *et al.*, 2018. Nephrotoxicity of Ciprofloxacin: Five Cases and a Review of the Literature. *Drug Saf Case Rep*. 18;5(1):17. doi: 10.1007/s40800-018-0073-4. PMID: 29671145; PMCID: PMC5906393
- Hashemi, A., Najafi, N., Behnaz, F., & Zare, A. 2010. Oral ciprofloxacin compared with intravenous ceftazidime on low-risk febrile neutropenia in acute lymphocytic leukemia. *Iranian Journal of Pediatric Hematology & Oncology*, 1(1), 8–12. https://www.sid.ir/en/VEWSSID/J_pdf/1001120100103.pdf
- Hill, D. L. *et al.*, 2020. Immune system development varies according to age, location, and anemia in African children. *Science Translational Medicine*, 12(529). <https://doi.org/10.1126/scitranslmed.aaw9522>
- Hoque, M. S., Sarkar, P. K., & Ahmed, A. N. U. 2020. Blood culture profile and antimicrobial resistance pattern: A study in intensive care unit (ICU) Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh. *Scholars Journal of Applied Medical Sciences*, 8(12), 2777–2783. <https://doi.org/10.36347/sjams.2020.v08i12.018>
- Jackson, T. J. *et al.*, 2022. Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics. *Archives of Disease in Childhood*, 108(3), 192–199. <https://doi.org/10.1136/archdischild-2021-323254>
- Joudeh, N. *et al.*, 2023. Epidemiology and source of infection in cancer patients with febrile neutropenia: An experience from a developing country. *BMC Infectious Diseases*, 23(1). <https://doi.org/10.1186/s12879-023-08058-6>
- Koenig, C., & Lehrnbecher, T. 2023. Diagnostics and therapy of paediatric patients with febrile neutropenia. *EJC Paediatric Oncology*, 2. <https://doi.org/10.1016/j.ejcped.2023.100116>
- Laoprasopwattana, K. *et al.*, 2012. Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. *The Pediatric Infectious Disease Journal*, 32(3). <https://doi.org/10.1097/INF.0b013e3182793610>
- Lehrnbecher, T. *et al.*, 2023. Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. *Journal of Clinical Oncology*, 41(9), 1774–1785. <https://doi.org/10.1200/jco.22.02224>
- Lyman, G. H., Abella, E., & Pettengell, R. 2014. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Critical Reviews in Oncology/Hematology*, 90(3), 190–199. <https://doi.org/10.1016/j.critrevonc.2013.12.006>
- Løhmann, D. J. A., *et al.*, 2018. Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. *Pediatric Blood & Cancer*, 65(9). <https://doi.org/10.1002/pbc.27231>
- Meckler, G., & Lindemulder, S. 2009. Fever and neutropenia in pediatric patients

- with cancer. *Emergency Medicine Clinics of North America*, 27(3), 525–541. <https://doi.org/10.1016/j.emc.2009.04.007>
- Mueller, E. L., Walkovich, K., Yanik, G. A., & Clark, S. J. 2015. Variation in management of fever and neutropenia among pediatric patients with cancer: A survey of providers in Michigan. *Pediatric Hematology and Oncology*, 32(5), 331–338. <https://doi.org/10.3109/08880018.2015.1036331>
- Murphy, K. *et al.*, 2022. *Janeway's Immunobiology*. W.W. Norton and Company
- Nabilah, A., Prabowo, W. C., & Kuncoro, H. 2023. Pengaruh kemoterapi terhadap kadar hematologi pada pasien kanker payudara di RSUD dr. Kanujoso Djatiwibowo Balikpapan. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 18, 12–20. <https://doi.org/10.25026/mpc.v18i1.697>
- Nguyen, S. N *et al.*, 2022. Clinical epidemiology characteristics and etiology of febrile neutropenia in children: Analysis of 421 cases. *Hematology Reports*, 14(3), 245–252. <https://doi.org/10.3390/hematolrep14030034>
- Radwan, R. A.-R. *et al.*, 2024. Non-cancer febrile neutropenia in children: Pathogens, antimicrobial susceptibilities, and outcomes. *Egyptian Pediatric Association Gazette*, 72(1). <https://doi.org/10.1186/s43054-024-00276-0>
- Raheja, R. *et al.*, 2023. Classification of chemotherapy-induced febrile neutropenic episodes into one of the three febrile neutropenic syndromes. *Cureus*. <https://doi.org/10.7759/cureus.42843>
- Rosales, C. 2018. Neutrophil: A cell with many roles in inflammation or several cell types? *Frontiers in Physiology*, 9. <https://doi.org/10.3389/fphys.2018.00113>
- Saifi, S. A. A., Adawi, B. A., & Burney, I. 2021. Patterns of bacterial isolates and their resistance to antibiotics in patients with chemotherapy-induced febrile neutropenia at a university hospital. *Oman Medical Journal*, 36(4). <https://doi.org/10.5001/omj.2021.87>
- Santschi, M. *et al.*, 2023. Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study. *PLoS ONE*, 18(8). <https://doi.org/10.1371/journal.pone.0287233>
- Seval, G. C., & Özcan, M., 2015. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients [Review of Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients]. *Journal of Clinical Medicine*, 4(3), 441. Multidisciplinary Digital Publishing Institute. <https://doi.org/10.3390/jcm4030441>
- Shahgholi, E. *et al.*, 2025. Predictive factors for duration of fever in neutropenic febrile episodes in children with cancer. *Journal of Comprehensive Pediatrics*, 16(1). <https://doi.org/10.5812/jcp-148125>
- Shariati A. *et al.*, 2022. The resistance mechanisms of bacteria against Ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. *Front Public Health*. Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. PMID: 36620240; PMCID: PMC9815622
- Sirkhazi, M. *et al.*, 2014. Bacterial spectrum, isolation sites and susceptibility patterns of pathogens in adult febrile neutropenic cancer patients at a

- specialist hospital in Saudi Arabia. *World Journal of Oncology*, 5, 196–204. <https://doi.org/10.14740/wjon850w>
- Skelly AC, Dettori JR, Brodt ED. 2012. Assessing bias: the importance of considering confounding. *Evid Based Spine Care J.* 3(1):9-12. doi: 10.1055/s-0031-1298595. PMID: 23236300; PMCID: PMC3503514.
- Soetardjo, I. A. dkk. 2024. *Pola mikroba dan kepekaan terhadap antimikroba (antibiogram) tahun 2023*. RS Sardjito. Yogyakarta
- Stern, A. et al., 2019. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. *Cochrane Database of Systematic Reviews*, 2019(1). <https://doi.org/10.1002/14651858.cd012184.pub2>
- Stohs, E. J., Abbas, A., & Freifeld, A. 2024. Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. *Transplant Infectious Disease*, 26(2). <https://doi.org/10.1111/tid.14236>
- Suryaningrat, F. R., Primadi, A., & Chairulfatah, A., 2019. *Perbandingan efektifitas antara monoterapi empiris seftazidime dan sefepim pada anak leukemia limfoblastik akut dengan demam neutropenia*. *Sari Pediatri*, 21(2), 81–88.
- Tan, X., et al., 2021. Comparative efficacy and safety of antipseudomonal β -lactams for pediatric febrile neutropenia. *Medicine*, 100(50). <https://doi.org/10.1097/md.00000000000027266>
- Thai T, Salisbury BH, Zito PM. Ciprofloxacin. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30571075.
- Villeneuve, S., & Aftandilian, C., 2022. Neutropenia and Infection Prophylaxis in Childhood Cancer [Review of Neutropenia and Infection Prophylaxis in Childhood Cancer]. *Current Oncology Reports*, 24(6), 671. Springer Science+Business Media. <https://doi.org/10.1007/s11912-022-01192-5>
- Wingard, J. R. 2024. *Overview of neutropenic fever syndromes*. UpToDate. <https://www.uptodate.com/contents/overview-of-neutropenic-fever-syndromes/print>
- Yılmaz, Ş., Ören, H., Demircioğlu, F., & rken, G. i. 2008. Assessment Of Febrile Neutropenia Episodes In Children With Acute Leukemia Treated With Bfm Protocols. *Pediatric Hematology and Oncology*, 25(3), 195. <https://doi.org/10.1080/08880010801938231>